$13.58
00.00%
Last update: Jul 19, 4:00 PM
15 minutes delayed
Comments
Loading...
Stoke Therapeutics
STOKNASDAQ
Unlock major analysts' bullish and bearish positions by joining Benzinga Edge.
Stoke Therapeutics (NASDAQ:STOK) Stock, Analyst Ratings, Price Targets, Forecasts
Stoke Therapeutics Inc has a consensus price target of $24 based on the ratings of 10 analysts. The high is $50 issued by Jefferies on January 31, 2022. The low is $12 issued by B of A Securities on May 1, 2023. The 3 most-recent analyst ratings were released by Wedbush, Needham, and HC Wainwright & Co. on July 11, 2024, June 28, 2024, and May 7, 2024, respectively. With an average price target of $24.67 between Wedbush, Needham, and HC Wainwright & Co., there's an implied 81.64% upside for Stoke Therapeutics Inc from these most-recent analyst ratings.
Analyst Firms Making Recommendations1
Wedbush
Needham
HC Wainwright & Co.
Canaccord Genuity
JP Morgan
1calculated from analyst ratings
Analyst Ratings for Stoke Therapeutics
| Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
| 07/11/2024 | Buy Now | 25.18% | Wedbush | Laura Chico | $17 → $17 | Reiterates | Outperform → Outperform | Get Alert |
| 06/28/2024 | Buy Now | 62% | Needham | Joseph Stringer | $22 → $22 | Reiterates | Buy → Buy | Get Alert |
| 05/07/2024 | Buy Now | 157.73% | HC Wainwright & Co. | Andrew Fein | → $35 | Reiterates | Buy → Buy | Get Alert |
| 05/07/2024 | Buy Now | 47.28% | Canaccord Genuity | Sumant Kulkarni | $21 → $20 | Maintains | Buy | Get Alert |
| 05/06/2024 | Buy Now | 62% | Needham | Joseph Stringer | → $22 | Reiterates | Buy → Buy | Get Alert |
| 04/11/2024 | Buy Now | 62% | Needham | Joseph Stringer | → $22 | Reiterates | Buy → Buy | Get Alert |
| 04/04/2024 | Buy Now | — | Cantor Fitzgerald | Charles Duncan | — | Reiterates | → Overweight | Get Alert |
| 03/26/2024 | Buy Now | 157.73% | HC Wainwright & Co. | Andrew Fein | → $35 | Reiterates | Buy → Buy | Get Alert |
| 03/26/2024 | Buy Now | 25.18% | Wedbush | Laura Chico | $13 → $17 | Maintains | Outperform | Get Alert |
| 03/26/2024 | Buy Now | 54.64% | Canaccord Genuity | Sumant Kulkarni | $18 → $21 | Maintains | Buy | Get Alert |
| 03/26/2024 | Buy Now | -4.27% | JP Morgan | Jessica Fye | $6 → $13 | Maintains | Neutral | Get Alert |
| 03/26/2024 | Buy Now | — | TD Cowen | Yaron Werber | — | Upgrade | Hold → Buy | Get Alert |
| 03/26/2024 | Buy Now | 62% | Needham | Joseph Stringer | $14 → $22 | Maintains | Buy | Get Alert |
| 02/16/2024 | Buy Now | 3.09% | Needham | Joseph Stringer | → $14 | Reiterates | Buy → Buy | Get Alert |
| 11/07/2023 | Buy Now | 3.09% | Needham | Joseph Stringer | $25 → $14 | Maintains | Buy | Get Alert |
| 08/08/2023 | Buy Now | 3.09% | Cantor Fitzgerald | Charles Duncan | $18 → $14 | Maintains | Overweight | Get Alert |
| 08/08/2023 | Buy Now | 69.37% | Credit Suisse | Judah Frommer | → $23 | Reiterates | Outperform → Outperform | Get Alert |
| 08/08/2023 | Buy Now | 157.73% | HC Wainwright & Co. | Andrew Fein | → $35 | Reiterates | Buy → Buy | Get Alert |
| 08/07/2023 | Buy Now | 84.09% | Needham | Joseph Stringer | → $25 | Reiterates | → Buy | Get Alert |
| 07/31/2023 | Buy Now | 157.73% | HC Wainwright & Co. | Andrew Fein | → $35 | Reiterates | Buy → Buy | Get Alert |
| 06/26/2023 | Buy Now | 84.09% | Needham | Joseph Stringer | → $25 | Reiterates | Buy → Buy | Get Alert |
| 06/08/2023 | Buy Now | 157.73% | HC Wainwright & Co. | Andrew Fein | → $35 | Reiterates | Buy → Buy | Get Alert |
| 05/23/2023 | Buy Now | 84.09% | Cantor Fitzgerald | Charles Duncan | $20 → $25 | Maintains | Overweight | Get Alert |
| 05/05/2023 | Buy Now | 106.19% | Credit Suisse | Judah Frommer | → $28 | Reiterates | → Outperform | Get Alert |
| 05/05/2023 | Buy Now | 157.73% | HC Wainwright & Co. | Andrew Fein | → $35 | Reiterates | → Buy | Get Alert |
| 05/05/2023 | Buy Now | 47.28% | Needham | Joseph Stringer | → $20 | Reiterates | → Buy | Get Alert |
| 05/01/2023 | Buy Now | -11.63% | B of A Securities | Greg Harrison | $9 → $12 | Upgrade | Underperform → Neutral | Get Alert |
| 04/26/2023 | Buy Now | 76.73% | Canaccord Genuity | Sumant Kulkarni | → $24 | Assumes | → Buy | Get Alert |
| 03/16/2023 | Buy Now | 84.09% | Needham | Joseph Stringer | → $25 | Reiterates | → Buy | Get Alert |
| 03/07/2023 | Buy Now | 47.28% | Cantor Fitzgerald | Charles Duncan | → $20 | Reiterates | → Overweight | Get Alert |
| 03/07/2023 | Buy Now | 84.09% | Wedbush | Laura Chico | $33 → $25 | Maintains | Outperform | Get Alert |
| 03/07/2023 | Buy Now | 106.19% | Credit Suisse | Judah Frommer | $32 → $28 | Maintains | Outperform | Get Alert |
| 03/07/2023 | Buy Now | 157.73% | HC Wainwright & Co. | Andrew Fein | → $35 | Reiterates | → Buy | Get Alert |
| 03/07/2023 | Buy Now | 84.09% | Needham | Joseph Stringer | → $25 | Reiterates | → Buy | Get Alert |
| 01/11/2023 | Buy Now | 135.64% | Credit Suisse | Judah Frommer | $38 → $32 | Maintains | Outperform | Get Alert |
| 12/05/2022 | Buy Now | 157.73% | HC Wainwright & Co. | Andrew Fein | $70 → $35 | Maintains | Buy | Get Alert |
| 11/15/2022 | Buy Now | 179.82% | Credit Suisse | Judah Frommer | $50 → $38 | Maintains | Outperform | Get Alert |
| 11/14/2022 | Buy Now | 84.09% | Needham | Joseph Stringer | $50 → $25 | Maintains | Buy | Get Alert |
| 08/08/2022 | Buy Now | 268.19% | Needham | Joseph Stringer | $65 → $50 | Maintains | Buy | Get Alert |
| 05/26/2022 | Buy Now | 179.82% | Cantor Fitzgerald | Charles Duncan | $68 → $38 | Maintains | Overweight | Get Alert |
| 03/16/2022 | Buy Now | 194.55% | B of A Securities | Greg Harrison | $43 → $40 | Maintains | Buy | Get Alert |
| 01/31/2022 | Buy Now | 268.19% | Jefferies | Suji Jeong | → $50 | Initiates | → Buy | Get Alert |
| 12/03/2021 | Buy Now | 216.64% | B of A Securities | Greg Harrison | — | Initiates | → Buy | Get Alert |
| 11/22/2021 | Buy Now | 201.91% | JP Morgan | Jessica Fye | — | Upgrade | Neutral → Overweight | Get Alert |
FAQ
What is the target price for Stoke Therapeutics (STOK) stock?
The latest price target for Stoke Therapeutics (NASDAQ:STOK) was reported by Wedbush on July 11, 2024. The analyst firm set a price target for $17.00 expecting STOK to rise to within 12 months (a possible 25.18% upside). 20 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Stoke Therapeutics (STOK)?
The latest analyst rating for Stoke Therapeutics (NASDAQ:STOK) was provided by Wedbush, and Stoke Therapeutics reiterated their outperform rating.
When was the last upgrade for Stoke Therapeutics (STOK)?
The last upgrade for Stoke Therapeutics Inc happened on March 26, 2024 when TD Cowen raised their price target to N/A. TD Cowen previously had a hold for Stoke Therapeutics Inc.
When was the last downgrade for Stoke Therapeutics (STOK)?
There is no last downgrade for Stoke Therapeutics.
When is the next analyst rating going to be posted or updated for Stoke Therapeutics (STOK)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Stoke Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Stoke Therapeutics was filed on July 11, 2024 so you should expect the next rating to be made available sometime around July 11, 2025.
Is the Analyst Rating Stoke Therapeutics (STOK) correct?
While ratings are subjective and will change, the latest Stoke Therapeutics (STOK) rating was a reiterated with a price target of $17.00 to $17.00. The current price Stoke Therapeutics (STOK) is trading at is $13.58, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.